Daito Pharmaceutical CoTSE:4577 -1.37%71 EBITDA Margin % is 24.26% as of Nov. 2025, which is 34% above its 10-year median of 18.06. GuruFocus rates TSE:4577 with a GF Score™ of 71/100 and a GF Value™ of 円1,276.34 (Fairly Valued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Daito Pharmaceutical Co ranks better than 69.01% on this metric.
Daito Pharmaceutical Co (TSE:4577) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Daito Pharmaceutical Co EBITDA Margin % Related Terms
Daito Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Daito Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daito Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daito Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Daito Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daito Pharmaceutical Co (TSE:4577) has a EBITDA Margin % of 24.26% as of Nov. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Daito Pharmaceutical Co and its competitors. This is 34% above median its historical median of 18.06. Over the past decade, Daito Pharmaceutical Co's EBITDA Margin % has ranged from 14.64 to 23.10. According to the industry distribution chart, Daito Pharmaceutical Co ranks #296 out of 955 companies in the Drug Manufacturers industry, placing it in the top 31%.
Is Daito Pharmaceutical Co's EBITDA Margin % too high?
Daito Pharmaceutical Co's current EBITDA Margin % of 24.26% is 34% above median its 10-year median of 18.06. Over the past 10 years, this metric has ranged from a low of 14.64 to a high of 23.10. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Daito Pharmaceutical Co's value of 24.26% is 95% above this industry median. Based on the distribution chart, Daito Pharmaceutical Co ranks #296 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daito Pharmaceutical Co has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Daito Pharmaceutical Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Daito Pharmaceutical Co ranks #296 out of 955 companies for EBITDA Margin %. This puts Daito Pharmaceutical Co in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Daito Pharmaceutical Co's value of 24.26% is 95% above this benchmark. Historically, Daito Pharmaceutical Co's own EBITDA Margin % has ranged from 14.64 to 23.10 over the past decade. While the company's 10-year median is 18.06 vs. the industry median of 12.44, Daito Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daito Pharmaceutical Co's current EBITDA Margin % of 24.26% is 95% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Daito Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daito Pharmaceutical Co's current EBITDA Margin % is 24.26%, which is 34% above median its own 10-year median of 18.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daito Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Daito Pharmaceutical Co (TSE:4577) is currently considered Fairly Valued. The stock's GF Value™ is 円1,276.34, compared to a current price of 円1,224.00 — trading 4.1% below its estimated fair value. The current EBITDA Margin % is 24.26%, which is 34% above median its 10-year median of 18.06 and 95% above the Drug Manufacturers industry median of 12.44. Daito Pharmaceutical Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Daito Pharmaceutical Co (TSE:4577), the current EBITDA Margin % is 24.26% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daito Pharmaceutical Co (TSE:4577) Overvalued in 2026?
Based on GuruFocus' analysis, Daito Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円1,224.00 is trading 4.1% below its estimated GF Value™ of 円1,276.34.
GuruFocus considers Daito Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4577:
EBITDA Margin %: 24.26% (34% above median its 10-year median of 18.06)
GF Value™: 円1,276.34 vs. price of 円1,224.00 (4.1% below fair value)
Industry Position: 95% above the Drug Manufacturers median (#296 of 955)
No single metric tells the full story. See the TSE:4577 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4577 has been successfully added to your 
